NEW YORK, NY--(Marketwired - Sep 29, 2017) - Rising India's (
Products include solutions for muscle and joint pain, back pain, neuropathy/nerve pain and arthritis. TSW Pain, a topical pain relief cream for muscle and joint relief, is currently under testing to meet FDA requirements and Rising execs are confident it will hit the market sometime during Q4.
The Company also announces today a trial run of its Clinical Strength Peptide Serum for scar and skin repair. The serum produces visible results with an effective ingredient base and delivery system and Rising BioSciences is launching a sample run for a limited number of subscribers to our newsletter. All you have to do to reserve your sample is visit www.RisingBiosciences.com, scroll to the bottom of the home page and 'Subscribe' to our newsletter while supplies last.
"We have received an overwhelmingly positive response to its trial run for TSW Pain and expect similar feedback for our clinical strength peptide serum," states Doug Bowes, Director of Brand Development.
As well, CEO Robert Weber has been working toward an official name and ticker change for Rising India, Inc. and has retained the services of the same attorney that assisted in successfully attaining the name and symbol change for sister company, PAO Group, Inc. (
$RSII on Twitter for LIVE company updates! www.twitter.com/risingindiausa
Forward-Looking Statements: Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications, which may arise, could prevent the prompt implementation of any strategically significant plan(s) outlined above. The Company undertakes no duty to revise or update any forward- looking statements to reflect events or circumstances after the date of this release.
Contact Information:
RISING INDIA CONTACT:
Investor Relations
IR@RisingIndiaUSA.com